These beneficial changes may result from coordinate regulation of hepatic and intestinal BA metabolism through the FXR/FGF15/CYP7A1 and LXRα/β/ABCG5/8 signaling pathways, ultimately contributing to improvements in glycolipid metabolism and slowing the progression of T2DM. The gene discussed is NR1H3; the disease is type 2 diabetes mellitus.